Geiparvarin analogues. 4. Synthesis and cytostatic activity of geiparvarin analogues bearing a carbamate moiety or a furocoumarin fragment on the alkenyl side chain. 1994

S Manfredini, and P G Baraldi, and R Bazzanini, and M Guarneri, and D Simoni, and J Balzarini, and E De Clercq
Dipartimento di Scienze Farmaceutiche, Università di Ferrara, Italy.

As a continuation of previous studies on the synthesis and antitumor activity of geiparvarin analogues bearing a carbamate moiety in the alkyl side chain, a series of N-substituted [(E)-3-(4,5-dihydro-5,5-dimethyl-4-oxo-2-furanyl)-2- butenyl]carbamates (15a-f) were synthesized and tested with the objective to investigate the reason for the marked difference of cytostatic activity found between alkyl and phenyl derivatives. A series of compounds, characterized by different physicochemical properties, were designed in order to study this hypothesis. Moreover, to further investigate the modification of the alkenyl side chain, (E)- and (Z)-[2-(4,5-dihydro-5,5-dimethyl-4-oxo-2-furanyl)propenyl]-7H-furo[3,2- g][1]benzopyran-7-one (11a,b) were synthesized, the latter compounds being the combination of two units, namely, the 3(2H)-furanone ring system endowed with potent alkylating properties and the furocoumarin portion which binds to DNA resulting in potential DNA-targeted alkylating agents. The compounds were tested for their cytostatic activity against proliferation of murine (L1210) and human (Molt/4, CEM, or MT-4) tumor cells. The highest cytostatic activity found within both series of carbamic derivatives (15a-d,k and 15e,g-j) was associated with the highest global lipophilicity. With regard to compounds 11a,b, the cytostatic activity of (Z)-furocoumarin 11b might be related to a specific interaction with DNA (i.e., intercalation).

UI MeSH Term Description Entries
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D011564 Furocoumarins Polycyclic compounds consisting of a furan ring fused with coumarin. They commonly occur in PLANTS, especially UMBELLIFERAE and RUTACEAE, as well as PSORALEA. Furanocoumarin,Furanocoumarins,Furocoumarin,Psoralens,Angelicins
D002219 Carbamates Derivatives of carbamic acid, H2NC( Carbamate,Aminoformic Acids,Carbamic Acids,Acids, Aminoformic,Acids, Carbamic
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003374 Coumarins Synthetic or naturally occurring substances related to coumarin, the delta-lactone of coumarinic acid. 1,2-Benzopyrone Derivatives,1,2-Benzopyrones,Coumarin Derivative,Coumarine,1,2-Benzo-Pyrones,Benzopyran-2-ones,Coumarin Derivatives,Coumarines,1,2 Benzo Pyrones,1,2 Benzopyrone Derivatives,1,2 Benzopyrones,Benzopyran 2 ones,Derivative, Coumarin,Derivatives, 1,2-Benzopyrone,Derivatives, Coumarin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics

Related Publications

S Manfredini, and P G Baraldi, and R Bazzanini, and M Guarneri, and D Simoni, and J Balzarini, and E De Clercq
September 2010, Bioorganic & medicinal chemistry,
S Manfredini, and P G Baraldi, and R Bazzanini, and M Guarneri, and D Simoni, and J Balzarini, and E De Clercq
October 1994, Farmaco (Societa chimica italiana : 1989),
S Manfredini, and P G Baraldi, and R Bazzanini, and M Guarneri, and D Simoni, and J Balzarini, and E De Clercq
September 2017, European journal of medicinal chemistry,
S Manfredini, and P G Baraldi, and R Bazzanini, and M Guarneri, and D Simoni, and J Balzarini, and E De Clercq
May 2006, Journal of peptide science : an official publication of the European Peptide Society,
S Manfredini, and P G Baraldi, and R Bazzanini, and M Guarneri, and D Simoni, and J Balzarini, and E De Clercq
June 2015, European journal of medicinal chemistry,
S Manfredini, and P G Baraldi, and R Bazzanini, and M Guarneri, and D Simoni, and J Balzarini, and E De Clercq
April 2012, Steroids,
S Manfredini, and P G Baraldi, and R Bazzanini, and M Guarneri, and D Simoni, and J Balzarini, and E De Clercq
September 1997, Anti-cancer drug design,
S Manfredini, and P G Baraldi, and R Bazzanini, and M Guarneri, and D Simoni, and J Balzarini, and E De Clercq
December 2019, Journal of agricultural and food chemistry,
S Manfredini, and P G Baraldi, and R Bazzanini, and M Guarneri, and D Simoni, and J Balzarini, and E De Clercq
January 2006, Current medicinal chemistry,
S Manfredini, and P G Baraldi, and R Bazzanini, and M Guarneri, and D Simoni, and J Balzarini, and E De Clercq
January 2001, European journal of medicinal chemistry,
Copied contents to your clipboard!